{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:54:51Z","timestamp":1790891691590,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ucl.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:38:15Z","timestamp":1785271095000},"page":"539-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in Bladder-Sparing Strategies for Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Rainjade","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Zibelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Karen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ucl.2026.06.004_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.004_bib2","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.004_bib3","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1200\/JCO.2024.42.16_suppl.4564","article-title":"Study EV-103: neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)\u20142-year event-free survival and safety data for Cohort H","volume":"42","author":"O\u2019Donnell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.004_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.004_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"issue":"33","key":"10.1016\/j.ucl.2026.06.004_bib6","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.004_bib7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.06.004_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041005","article-title":"Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance","volume":"10","author":"Hafeez","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.004_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","volume":"87","author":"Huddart","year":"2025","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.004_bib10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.juro.2013.10.142","article-title":"Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate","volume":"191","author":"Lavery","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.004_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0022-5347(05)00995-X","article-title":"Cancer specific outcomes in patients with pT0 disease following radical cystectomy","volume":"175","author":"Palapattu","year":"2006","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.ucl.2026.06.004_bib12","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.21475","article-title":"Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival","volume":"104","author":"Volkmer","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.004_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00345-012-0855-8","article-title":"Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease","volume":"30","author":"Tollefson","year":"2012","journal-title":"World J Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.06.004_bib14","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.004_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.004_bib16","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.004_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.004_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.urpr.2017.07.001","article-title":"The promise and disappointment of neoadjuvant chemotherapy and transurethral resection for muscle invasive bladder cancer: updated results and long-term followup","volume":"5","author":"Yap","year":"2018","journal-title":"Urol Pract"},{"issue":"23","key":"10.1016\/j.ucl.2026.06.004_bib19","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ucl.2026.06.004_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.004_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euf.2020.01.007","article-title":"Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives","volume":"6","author":"Gakis","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.004_bib22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","article-title":"Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base","volume":"88","author":"Gray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.004_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","article-title":"Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.06.004_bib24","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.juro.2009.01.115","article-title":"Sequential treatment approach myoinvasive urothelial cancer: Phase II Southwest Oncology Group trial (S0219)","volume":"181","author":"White","year":"2009","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.004_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.euf.2016.12.005","article-title":"Absence of tumor on repeat transurethral resection of bladder tumor does not predict final pathologic T0 stage in bladder cancer treated with radical cystectomy","volume":"4","author":"Kukreja","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.004_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.urology.2014.03.040","article-title":"The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer","volume":"84","author":"Reese","year":"2014","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.004_bib27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/JU.0000000000001602","article-title":"Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: a prospective trial","volume":"205","author":"Zibelman","year":"2021","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.004_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000180","article-title":"Long-term oncologic outcomes in patients with muscle invasive bladder cancer misclassified as achieving a complete clinical response to neoadjuvant chemotherapy","volume":"2","author":"Chung","year":"2024","journal-title":"JU Open Plus"},{"issue":"16","key":"10.1016\/j.ucl.2026.06.004_bib29","article-title":"A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)","volume":"40","author":"Iyer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.004_bib30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.004_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","article-title":"Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial","volume":"86","author":"Plimack","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.004_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.004_bib33","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.ucl.2026.06.004_bib34","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ucl.2026.06.004_bib35","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ucl.2026.06.004_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.004_bib37","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle Invasive Bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ucl.2026.06.004_bib38","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","article-title":"Circulating tumor DNA (ctDNA) patients muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) NIAGARA","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.004_bib39","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"CtDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.004_bib40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2026.06.004_bib41","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2021.39.15_suppl.4503","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257","volume":"39","author":"Galsky","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2026.06.004_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2533449123","article-title":"Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer","volume":"123","author":"Galsky","year":"2026","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ucl.2026.06.004_bib43","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S2666-1683(25)02515-7","article-title":"INSITE Trial: improving identification of muscle-invasive bladder cancer not detected on systematic endoscopic evaluation","volume":"82","author":"Kutikov","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"10.1016\/j.ucl.2026.06.004_bib44","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.urolonc.2022.02.009","article-title":"The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial","volume":"40","author":"Daneshmand","year":"2022","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.004_bib45","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(25)00358-4","volume":"26","author":"Necchi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ucl.2026.06.004_bib46","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.004_bib47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41591-024-03324-9","article-title":"Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:58:51Z","timestamp":1790888331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0094014326000571"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.004","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in Bladder-Sparing Strategies for Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}